Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice

被引:0
|
作者
Kaur, Gurveer [1 ]
Nwabufo, Chukwunonso K. [1 ,2 ,3 ]
机构
[1] OneDrug Inc, Toronto, ON, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada
[3] Hosp Sick Children, Program Translat Med, Toronto, ON, Canada
来源
PHARMACOGENETICS AND GENOMICS | 2024年 / 34卷 / 07期
基金
加拿大健康研究院;
关键词
adverse drug reactions; healthcare provider; implementation; patient; personalized medicine; pharmacogenetics; pharmacogenetic testing device; point-of-care; PHARMACISTS PERCEPTION; CONTEXT; EXPERIENCES; SUPPORT; POINT;
D O I
10.1097/FPC.0000000000000541
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
ObjectiveThis study aims to understand patient and healthcare provider perspectives on the integration and application of pharmacogenetics (PGx) testing in routine clinical practice.MethodsTwo anonymous online surveys were distributed globally for healthcare providers and patients respectively on the Qualtrics platform (version 3.24). The surveys were distributed through social platforms, email, and posters with QR codes from 27 October 2023 to 7 March 2024. The surveys evaluated participant familiarity with PGx, previous experience with PGx testing, perceived implementation challenges, and opinions on point-of-care (PoC) PGx testing devices.ResultsThis study collected 78 responses from healthcare providers and 98 responses from patients. The results revealed that 64% of healthcare providers had some level of familiarity with PGx, however, PGx testing in clinical practice was low. The primary challenges identified by healthcare providers included limited access to testing and lack of knowledge on PGx test interpretation. In contrast, 52% of patient respondents were aware of PGx testing, with a significant association between awareness and positive opinions toward PGx. Both healthcare providers and patients recognized the value of PoC PGx testing devices, with 98% of healthcare providers and 71% of patients believing PoC devices would improve the accessibility and implementation of PGx testing. Comparative analysis revealed a statistically significant difference in PGx awareness between healthcare providers and patients, with providers being more informed.ConclusionImproved PGx awareness, training, clinical guidelines, and PoC PGx testing devices may help promote the implementation of PGx-guided treatments in routine clinical practice.
引用
收藏
页码:236 / 245
页数:10
相关论文
共 50 条
  • [31] Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups
    Dietz, Nicholas
    Ruff, Christian
    Giugliano, Robert P.
    Mercuri, Michele F.
    Antman, Elliott M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 317 : 159 - 166
  • [32] Implementation of PROMs and PREMs in routine clinical practice: Standardized evaluation of their impact on patients and healthcare professionals
    Amat-Fernandez, Clara
    Bach, Anna
    Briseno, Renata
    Redondo-Pachon, Dolores
    Pardo, Yolanda
    Ferrer, Montse
    Garin, Olatz
    QUALITY OF LIFE RESEARCH, 2024, 33 : S120 - S120
  • [33] Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention
    Cooke, Alexis
    Saleem, Haneefa
    Hassan, Saria
    Mushi, Dorothy
    Mbwambo, Jessie
    Lambdin, Barrot
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2019, 14 (1) : 3
  • [34] Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention
    Alexis Cooke
    Haneefa Saleem
    Saria Hassan
    Dorothy Mushi
    Jessie Mbwambo
    Barrot Lambdin
    Addiction Science & Clinical Practice, 14
  • [35] Provider education to promote implementation of clinical practice guidelines
    Ockene, JK
    Zapka, JG
    CHEST, 2000, 118 (02) : 33S - 39S
  • [36] At-risk patient and healthcare provider perspectives on clinical trial participation for ductal carcinoma in situ.
    Adams, Elizabeth
    Kulkarni, Swati
    Zheng, Veronica
    Warwar, Samantha Ahsan
    Brown, Denisha
    Schulte, Lauren
    Cooper, Robin
    Labomascus, Bazil
    Bhavsar, Erica B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?
    Baranova, E. V.
    Asselbergs, F. W.
    de Boer, A.
    Maitland-van der Zee, A. H.
    CURRENT MOLECULAR MEDICINE, 2014, 14 (07) : 841 - 848
  • [38] Implementation of thyroid-related patient-reported outcomes in routine clinical practice
    Cramon, Per Karkov
    Bjorner, Jakob Bue
    Groenvold, Mogens
    Boesen, Victor Brun
    Bonnema, Steen Joop
    Hegedus, Laszlo
    Feldt-Rasmussen, Ulla
    Rasmussen, Ase Krogh
    Watt, Torquil
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [39] A QUALITATIVE EXPLORATION OF PATIENT AND HEALTHCARE PROVIDER PERSPECTIVES ON OXYBATE TREATMENTS FOR NARCOLEPSY
    Loomer, S.
    Rene, C.
    Drachenberg, C.
    Candler, S.
    Bates, D.
    Akerman, S.
    VALUE IN HEALTH, 2024, 27 (06) : S304 - S304
  • [40] TRANSGENDER PATIENT AND GENDER AFFIRMING CARE PROVIDER PERSPECTIVES ON MISGENDERING IN HEALTHCARE
    Okamuro, Kyle
    Blumenthal, Jill
    Card, Allan
    Cohen, Tara
    Dolendo, Isabella
    Anger, Jennifer
    NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S265 - S266